Aligos Therapeutics, Inc. (ALGS) Revenue History
Annual and quarterly revenue from 2018 to present
ALGS Revenue Over Time (2018–2025)
ALGS Revenue Growth History
2 of 4 years with positive growth- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- +219.0%
- FY2023 revenue growth
- +11.7%
- FY2024 revenue growth
- -74.6%
- FY2025 revenue growth
- -44.6%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $2.8M | +810.0% |
| Q4 2025 | $169K | -73.1% |
| Q3 2025 | $741K | -41.6% |
| Q2 2025 | $965K | -9.0% |
| Q1 2025 | $311K | -68.5% |
| Q4 2024 | $629K | -76.5% |
| Q3 2024 | $1.3M | -60.8% |
| Q2 2024 | $1.1M | -84.6% |
Multi-year avg. share of annual revenue by fiscal quarter
ALGS Revenue Analysis (2018–2025)
Current Revenue & Growth
As of June 28, 2026, Aligos Therapeutics, Inc. (ALGS) generated trailing twelve-month (TTM) revenue of $4.7 million, reflecting explosive growth of +810.0% year-over-year. The most recent quarter (Q1 2026) recorded $2.8 million in revenue, up 1574.6% sequentially.
Historical Growth Trajectory
ALGS's historical revenue data shows a 3-year CAGR of -46.0%. Aligos Therapeutics, Inc.'s highest annual revenue of $15.5 million was recorded in 2023.
Peer Comparison
Compared to Healthcare sector peers — including ARWR (+14.1% YoY), HALO (+39.1% YoY), and RCUS (+67.4% YoY) — ALGS has outperformed the peer group in revenue growth. Compare ALGS vs ARWR →
ALGS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ALGSCurrent | $5M | +810.0% | - | -4024.9% | |
 ARWR | $829M | +14.1% | +56.6% | 11.9% | |
 HALO | $1.4B | +39.1% | +39.2% | 58.4% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 GILD | $29.4B | +3.5% | +3.6% | 39.7% | |
 VRTX | $12.1B | +10.4% | +14.2% | 39.4% |
ALGS Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.2M | -44.6% | $1.3M | 57.5% | $-87,985,000 | -4024.9% |
| 2024 | $3.9M | -74.6% | $3.9M | 100.0% | $-89,154,000 | -2259.9% |
| 2023 | $15.5M | +11.7% | $15.5M | 100.0% | $-88,127,000 | -567.5% |
| 2022 | $13.9M | +219.0% | $13.9M | 100.0% | $-97,580,000 | -701.7% |
| 2021 | $4.4M | - | $4.4M | 100.0% | $-128,321,000 | -2943.8% |
| 2020 | $0 | - | $-3,325,000 | - | $-97,834,000 | - |
| 2019 | $0 | - | $-2,299,000 | - | $-54,043,000 | - |
| 2018 | $0 | - | $-1,291,000 | - | $-13,661,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ALGS — Frequently Asked Questions
Quick answers to the most common questions about buying ALGS stock.
Is ALGS's revenue growth accelerating or slowing?
ALGS revenue growth is accelerating. TTM revenue reached $5M, up +810.0% year-over-year — ahead of the 5-year CAGR of N/A. This indicates the business is expanding faster than its historical baseline.
What is ALGS's revenue history from 2018 to 2026?
Aligos Therapeutics, Inc. (ALGS) revenue history spans 2018 to 2026. TTM revenue as of 2026 is $5M, growing at +810.0% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ALGS's long-term revenue growth rate (CAGR)?
Aligos Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +810.0% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ALGS.
Why does ALGS's quarterly revenue fluctuate?
ALGS quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Aligos Therapeutics, Inc.'s revenue data from 2018 to 2026 shows full historical quarterly detail on this page.
How is ALGS's revenue distributed by segment?
ALGS reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ALGS's revenue compare to industry peers?
Aligos Therapeutics, Inc. (ALGS) with TTM revenue of $5M and +810.0% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.